|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Beral V et al. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360(9337):942-4. Abstract
Black DM et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41. Abstract
Braithwaite RS et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18(11):937-47. Abstract
Brufsky A et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). San Antonio Breast Cancer Symposium
2006;Abstract 107.
Brufsky A et al. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006b;33(2 Suppl 7):13-7. Abstract
Brufsky A et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). San Antonio Breast Cancer Symposium 2006c;Abstract 5060.
Chlebowski RT et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 2006a;98(24):1767-76. Abstract
Chlebowski RT et al. Mature analysis from the Women’s Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. Presentation. San Antonio Breast Cancer Symposium 2006b;Abstract 32.
Chlebowski RT et al. The Women’s Health Initiative randomized trial of calcium plus vitamin D: Effects on breast cancer and arthralgias. Proc ASCO 2006c;Abstract LBA6.
Chlebowski RT et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). Proc ASCO 2005;Abstract 10.
Coates AS et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25(5):486-92. Abstract
Coleman RE, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 511.
Cummings SR et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82. Abstract
Geisler J et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo controlled study. Eur J Cancer 2006;42(17):2968-75. Abstract
Grimes DA, Lobo RA. Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002;100(6):1344-53. Abstract
Howell A, on behalf of the ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Lonning PE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126-37. Abstract
Low AK et al. Hormone replacement therapy and coronary heart disease in women: A review of the evidence. Am J Med Sci 2002;324(4):180-4. Abstract
Mauriac L et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007;18(5):859-67. Epub 2007 Feb 14. Abstract
Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: A comparative review. Drug Saf 2006;29(9):785-801. Abstract
Nelson HD et al. Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002;288(7):872-81. Abstract
Pradhan AD et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women’s Health Initiative observational study. JAMA 2002;288(8):980-7. Abstract
Prentice RL et al. Low-fat dietary pattern and risk of invasive breast cancer: The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295(6):629-42. Abstract
Ravdin PM et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356(16):1670-4. Abstract
Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract
Vakaet LA, Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with five years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC). Poster. San Antonio Breast Cancer Symposium 2006;Abstract 2084.
Weiss LK et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 2002;100(6):1148-58. Abstract
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Sharon Giordano, MD, MPH
- Select publications
Rowan T Chlebowski, MD, PhD
- Select publications
Tumor Panel Case Discussion
- Select publications
INTERVIEWS (continued)
Jack Cuzick, PhD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
